Computationally Guided Design of Thermostable mutants of Neurotensin receptor1
神经降压素受体 1 热稳定突变体的计算引导设计
基本信息
- 批准号:8476236
- 负责人:
- 金额:$ 30.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-01 至 2015-05-31
- 项目状态:已结题
- 来源:
- 关键词:Adenosine A2A ReceptorAdrenergic ReceptorAlgorithmsBindingBiochemicalBudgetsCalibrationCellsCitiesCollaborationsComputer SimulationComputing MethodologiesCrystallizationDataDetergentsDiseaseDrug DesignDrug TargetingDrug abuseEnvironmentFeedbackFunctional disorderFundingG-Protein-Coupled ReceptorsGoalsGrowthGrowth FactorHomology ModelingHydrogen BondingIn VitroInterdisciplinary StudyLaboratoriesLigand BindingLigandsMalignant NeoplasmsMarketingMembraneMethodsModelingMolecular ConformationMolecular StructureMutagenesisMutationNational Institute of Neurological Disorders and StrokeNatureNeurotensinNeurotensin ReceptorsPeptidesPharmaceutical PreparationsPharmacologyPhasePlayPoint MutationPotential EnergyProcessProteinsRattusResearch PersonnelRoleSamplingScanningSchizophreniaSideSignal PathwaySolutionsStructureTechniquesTestingTimeUnited States National Institutes of HealthWorkbasecancer cellcostdesignexperienceflexibilityimprovedin vivoinhibitor/antagonistinnovationinsightinterdisciplinary approachinterdisciplinary collaborationmeetingsmimeticsmutantprotein purificationreceptorreconstitutionresearch studystemvalylleucine
项目摘要
DESCRIPTION (provided by applicant): Neurotensin receptors belong to the superfamily of peptide activated G protein-coupled receptors (GPCRs) and they are important drug targets to diseases such as schizophrenia and even cancer. The complexity in drug design for NTS1 and for many peptide activated GPCRs partly stems from the paucity of structural information, which could provide vital information for rational drug design. The barriers to pursuing structural and biophysical studies of membrane bound neurotensin receptors are due primarily to three challenges that are: 1.obtaining sufficient levels of expressed mammalian receptors, 2. functionally reconstituting them into membrane mimetics and 3. most importantly, stabilizing a particular inactive or active state conformation due to the conformational flexibility of GPCRs. While steps (1) and (2) are surmountable, step (3) the conformational flexibility in GPCRs, severely hampers the protein purification process for further crystallization or any other biophysical studies of GPCRs. Therefore meeting challenge (3) is critical in solving the macromolecular structure and ligand binding to GPCRs and requires a confluence of predictive computational models accompanied by experimental techniques. We propose to develop a computational method "LiticonDesign" that would enable design of thermally stable mutants of rat neurotensin receptor 1 (NTS1) (class A GPCRs in general). LiticonDesign will be based on the "Liticon", a predictive method that allows accurate modeling of various functional ligand stabilized conformational states of GPCRs. The predicted mutants of NTS1 will be expressed and tested for thermal stability and derive sufficient quantities of the pure functional receptor for structural studies. The results of this proposed work will provide a breakthrough method to obtain stable and functional pure protein of NTS1 which could be extended to other class A GPCRs. The proposed interdisciplinary collaboration is between Dr. Nagarajan Vaidehi (PI) at City of Hope, Dr. Reinhard Grisshammer NINDS/NIH and Dr. Christopher Tate (Univ. of Cambridge UK). Dr. Vaidehi has extensive experience in developing modeling techniques for GPCRs, while Dr. Tate is an expert in deriving thermostable mutants of GPCRs. Dr. Grisshammer is an expert on neurotensin receptors and their pharmacology. The budget is allocated only for Dr. Vaidehi, since Dr. Grisshammer is funded by the intramural funding in NINDS and Dr. Tate has sufficient funding for this work. The proposed work is ongoing in his laboratory.
描述(申请人提供):神经素受体属于肽激活的G蛋白偶联受体(GPCR)的超家族,它们是诸如精神分裂症甚至癌症等疾病的重要药物靶标。 NTS1和许多肽激活的GPCR的药物设计的复杂性部分源于结构信息的匮乏,这可能为理性药物设计提供重要信息。 追求膜结合神经蛋白受体的结构和生物物理研究的障碍主要是由于三个挑战,即:1。对足够水平的表达哺乳动物受体,2。在功能上重新构成膜模拟物和3个。最重要的是,最重要的是,特定的状态构型应稳定在适应性或活跃的状态构型中。虽然步骤(1)和(2)是可以克服的,但步骤(3)GPCR中的构象柔韧性,严重阻碍了进一步结晶或任何其他GPCR的生物物理研究的蛋白质纯化过程。因此,应对挑战(3)对于解决大分子结构和配体与GPCR的结合至关重要,并且需要伴随实验技术的预测计算模型汇合。 我们建议开发一种计算方法“ liticondesign”,该方法可以设计大鼠神经素受体1(NTS1)(通常是A类GPCR)的热稳定突变体。 Liticondesign将基于“ Liticon”,这是一种预测方法,允许对GPCR的各种功能配体稳定构象状态进行准确的建模。 NTS1的预测突变体将被表达和测试,以实现热稳定性,并得出足够数量的纯功能受体进行结构研究。这项提出的工作的结果将提供一种突破性的方法,以获得NTS1的稳定且功能性的纯蛋白质,该蛋白可以扩展到其他A类GPCR。 拟议的跨学科合作是在希望市的Nagarajan Vaidehi(PI)博士,Reinhard Grisshammer Ninds/NIH博士和Christopher Tate博士(英国剑桥大学)之间。 Vaidehi博士在开发GPCR的建模技术方面具有丰富的经验,而Tate博士是推导GPCR热稳定突变体的专家。 Grisshammer博士是神经辛受体及其药理学的专家。由于格里斯哈默(Grisshammer)博士是由尼德斯(Ninds)的校内资金资助,而泰特(Tate)博士为这项工作提供了足够的资金,因此预算仅为Vaidehi博士分配。拟议的工作正在他的实验室中进行。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nagarajan Vaidehi其他文献
Nagarajan Vaidehi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nagarajan Vaidehi', 18)}}的其他基金
Structural dynamics underlying GPCR-G protein selectivity
GPCR-G 蛋白选择性的结构动力学
- 批准号:
10379423 - 财政年份:2017
- 资助金额:
$ 30.78万 - 项目类别:
Structural dynamics underlying GPCR-G protein selectivity
GPCR-G 蛋白选择性的结构动力学
- 批准号:
10559695 - 财政年份:2017
- 资助金额:
$ 30.78万 - 项目类别:
Computationally Guided Design of Thermostable mutants of Neurotensin receptor1
神经降压素受体 1 热稳定突变体的计算引导设计
- 批准号:
8327192 - 财政年份:2011
- 资助金额:
$ 30.78万 - 项目类别:
Computationally Guided Design of Thermostable mutants of GPCR-transducer complexes
GPCR-转导复合物热稳定突变体的计算引导设计
- 批准号:
9279145 - 财政年份:2011
- 资助金额:
$ 30.78万 - 项目类别:
Computationally Guided Design of Thermostable mutants of Neurotensin receptor1
神经降压素受体 1 热稳定突变体的计算引导设计
- 批准号:
8084826 - 财政年份:2011
- 资助金额:
$ 30.78万 - 项目类别:
Computationally Guided Design of Thermostable mutants of GPCR-transducer complexes
GPCR-转导复合物热稳定突变体的计算引导设计
- 批准号:
8913703 - 财政年份:2011
- 资助金额:
$ 30.78万 - 项目类别:
GNEIMO: Generalized Internal Coordinate Molecular Dynamics Methods
GNEIMO:广义内坐标分子动力学方法
- 批准号:
7901558 - 财政年份:2008
- 资助金额:
$ 30.78万 - 项目类别:
GNEIMO: Generalized Internal Coordinate Molecular Dynamics Methods
GNEIMO:广义内坐标分子动力学方法
- 批准号:
7389080 - 财政年份:2008
- 资助金额:
$ 30.78万 - 项目类别:
GNEIMO: Generalized Internal Coordinate Molecular Dynamics Methods
GNEIMO:广义内坐标分子动力学方法
- 批准号:
8139915 - 财政年份:2008
- 资助金额:
$ 30.78万 - 项目类别:
GNEIMO: Generalized Internal Coordinate Molecular Dynamics Methods
GNEIMO:广义内坐标分子动力学方法
- 批准号:
7670409 - 财政年份:2008
- 资助金额:
$ 30.78万 - 项目类别:
相似国自然基金
内皮β3肾上腺素能受体调控线粒体功能参与血管衰老的作用研究
- 批准号:82370408
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
肾上腺素能受体激动剂引起睑板腺功能障碍发病的机制研究
- 批准号:82371024
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
心脏成纤维细胞β2-肾上腺素能受体对心衰小细胞外囊泡释放的作用机制研究
- 批准号:82370276
- 批准年份:2023
- 资助金额:47.00 万元
- 项目类别:面上项目
α1-和β3-肾上腺素能受体的荧光探针可视化研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
β2肾上腺素能受体调控皮肤角化细胞活化在慢性重叠型疼痛状态中的机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
相似海外基金
Multiple targets for beta adrenergic antagonist mediate wound healing
β 肾上腺素能拮抗剂的多个靶点介导伤口愈合
- 批准号:
10482306 - 财政年份:2023
- 资助金额:
$ 30.78万 - 项目类别:
Intensive Blood Pressure Control During Cardiotoxic Breast Cancer Treatment (PROTECT) Trial
心脏毒性乳腺癌治疗 (PROTECT) 试验期间强化血压控制
- 批准号:
10660289 - 财政年份:2023
- 资助金额:
$ 30.78万 - 项目类别:
Bedside to bench resources for lower urinary tract research
用于下尿路研究的床边到工作台资源
- 批准号:
10517227 - 财政年份:2022
- 资助金额:
$ 30.78万 - 项目类别:
Risk-Based Primary Prevention of Heart Failure
基于风险的心力衰竭一级预防
- 批准号:
10516468 - 财政年份:2022
- 资助金额:
$ 30.78万 - 项目类别:
Risk-Based Primary Prevention of Heart Failure
基于风险的心力衰竭一级预防
- 批准号:
10689211 - 财政年份:2022
- 资助金额:
$ 30.78万 - 项目类别: